For more than two decades, Maua enjoyed booming business propelled by the growth and sale of khat, known locally as miraa, a popular herb whose leaves and stems are chewed for the mild high they offer. But last year the UK, home to one of khat’s biggest markets, declared the stimulant a class C drug and banned all imports, prompting Maua’s rapid descent into economic purgatory.
Today, khat joined the range of prohibited substances that fall under the UK Misuse of Drugs Act 1971. Those who distribute this Class C drug can now face 14 years imprisonment – the same maximum sentence that applies to individuals who cause death by dangerous driving, and four years more than the maximum penalty for sexual assault. So what exactly is khat, and why has it attracted such harsh legislation? (See also: Khat: Update - Ban to be implemented on the 24th of June)
Police have been officially advised to use their discretion in deciding how to enforce the ban on qat, a mild herbal stimulant, that has been widely used in Britain's Somali, Yemeni and Ethiopian communities. Official guidelines from the Association of Chief Police Officers tells constables that in applying a "three strikes" enforcement policy they should take into account that qat has "historically not been a controlled drug and was part of the culture of certain communities linked to the Horn of Africa." (See also: Stimulant khat banned as illegal class C drug in UK)
The UK and the Netherlands commissioned distinguished scholars and experts to study the social and clinical harms of khat. These experts argued that any harms associated with khat did not require a criminal law response. In rejecting that conclusion and banning khat, these two governments have created an enabling environment for organized criminal networks and may exacerbate racial discrimination in drug law enforcement. Moreover, these policies put in danger the livelihood of thousands of people in some of the world’s lowest-income settings.
Khat is as potent as a strong cup of coffee and has no organised crime involvement – yet the government wants to spend £150m on a ban that would create far more severe problems. When the Advisory Council on the Misuse of Drugs, the government's expert advisors, were asked to consider khat, they said that it would be "inappropriate and disproportionate" to ban it. The cross-party home affairs select committee, on which I serve, produced a unanimous report opposing a ban. And yet the home secretary plans to do it anyway.
The leafy substance khat, grown by many Kenyan farmers, is of economic and cultural significance to many Africans. The UK government has decided, against the advice of its own experts, to treat khat as a class C drug to "protect vulnerable members of our communities". In July, UK Home Secretary Theresa May said khat would be banned "at the earliest possible opportunity" but a ban has yet to be imposed. A team of Kenyan MPs lobby the UK government not to follow suit.
A decision by the UK government to ban the stimulant khat later this year is facing fierce resistance in Kenya from those farming the mildly narcotic leaves for export. Local leaders are not happy with the UK's decision to reclassify khat as a class C drug. The local MP, Kubai Kiringo, tells me Kenya could reconsider its ties to Britain if the UK does not drop the ban. "We feel bitter and short-changed. We want the home secretary to revise her decision," he says. (See also: Harmless habit or dangerous drug?)
A clash between the home secretary, Theresa May, and her expert drugs advisory group is looming after it decided against banning qat, a mild herbal stimulant, traditionally used in Britain's Somali, Yemeni and Ethiopian communities. The Advisory Council on the Misuse of Drugs said there was insufficient evidence that Qat caused health or wider societal problems to justify a ban in Britain.
On the basis of the available evidence, the overwhelming majority of Council members consider that khat should not be controlled under the Misuse of Drugs Act 1971. In summary the reason for this is that, save for the issue of liver toxicity, although there may be a correlation or association between the use of khat and various negative social indicators, it is not possible to conclude that there is any causal link.
The Advisory Council on the Misuse of Drugs (ACMD) said there was "insufficient evidence" that khat caused health problems. The stimulant is traditionally used by members of the Somali, Yemeni and Ethiopian communities. It has been outlawed by the US and Canada and in most European countries, most recently by the Netherlands. The review was commissioned by the Home Office. The ACMD said there was "no evidence" khat was directly linked with serious or organised crime. (See also: Chewing over Khat prohibition)
Khat, a stimulant drug, is chewed by around 90,000 people in the east African and Yemeni communities in the UK. But now the Home Office is considering banning the substance. During the last election, pro-ban activists met politicians, offering them community votes. In return, they wanted their support for the ban on khat. Some politicians accepted the offer and supported the mission.
Calls for the herbal high khat to be banned in the UK have been renewed days before a government report into its usage is due to be published. Some members of the British-Somali community have been calling for years for khat to be made illegal. But traders say a ban would not mean an end to khat in the UK as, according to them, smuggled khat is still widely available in Europe and the US, although it is more expensive.
In the context of a fast changing and well documented market in legal highs, the case of khat (Catha edulis) provides an interesting anomaly. It is first of all a plant-based substance that undergoes minimal transformation or processing in the journey from farm to market. Secondly, khat has been consumed for hundreds if not thousands of years in the highlands of Eastern Africa and Southern Arabia. In European countries, khat use was first observed during the 1980s, but has only attracted wider attention in recent years.
A grey area has emerged between what is legal and what is not as states struggle with how to respond to the many new synthetic compounds emerging onto the market. Of the various types of ‘Legal highs’ the seminar focused on stimulants because of the parallels with the other main drug-policy issue of the moment; i.e. the status of traditional herbal stimulants. These older discussions have been reinvigorated by: Bolivia’s efforts to de-schedule coca-leaf at UN level; the debates on the status of khat between EU States, and of kratom across Asia; and the increasing stride of legitimate cannabis use on the domestic front, as in for example Spain.
Khat leaves are cultivated in the highlands of the Horn of Africa, Southern Arabia and along the East African coast. In many countries, chewing khat is an age-old tradition. More recently, the mass migration of people from the Horn of Africa has been associated with the spread of khat usage to neighbouring countries, Europe and the rest of the world. Exact numbers of regular khat users on a worldwide scale do not exist, however estimates range up to 20 million. This paper presents the challenges associated with the spread of khat consumption.
The study aims to review and analyse the varied East African discourses on the effects of khat use on libido, fertility, transmission of HIV, prostitution and rape. Khat is associated, by consumers and its detractors alike, with changes in libido and sexual performance. Although there is no evidence to support their claims, detractors of khat use argue that khat causes sexual violence, causes women to enter sex work, and that chewing causes the spread of sexually transmitted diseases, including the HIV virus.
The article reviews the status of khat, the most recent plant based psychoactive substance to reach a global market, and considers policy making processes in general and the framework of drug control in particular. The risk assessment and classification of psychoactive drugs is a contested arena where political, economic and moral agendas collide, leaving countries that have banned khat, with significant social costs. To best manage the risks arising from the increasing availability of khat it is therefore suggested to draft a regulatory framework with clear objectives and guiding principles.
Paul Griffiths, Dominique Lopez, Roumen Sedefov, Ana Gallegos, Brendan Hughes, André Noor, Luis Royuela
07 မေလ 2010
The aim of the study was to review the information available on the use of khat (Catha edulis) in the EU, and to assess the future use of this drug and related substances. Khat use sits awkwardly within the current EU reporting framework, and this hampers the production of a European-level analysis of the use of this drug. Why this is so, and what information is available at the European level, are the topics addressed in this paper. The analysis is extended to consider if the current evidence suggests that this drug, or synthetic variations of the psychoactive compounds it contains, are likely to play a greater role in the European drug scene of the future.